S. Margaret Paik to Disease-Free Survival
This is a "connection" page, showing publications S. Margaret Paik has written about Disease-Free Survival.
Connection Strength
0.086
-
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020 02 10; 38(5):444-453.
Score: 0.032
-
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 01; 20(1):88-99.
Score: 0.030
-
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep; 16(9):1037-1048.
Score: 0.024